Hypoxia inducible factor (HIF) as a model for studying inhibition of protein–protein interactions

The state of the art in identifying protein–protein interaction inhibitors of hypoxia inducible factor – a promising target for anticancer drug design – is described.

• Publication year

  2017

• Venue

  Chemical Science

• Publication date

  2017-04-26

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1039/c7sc00388aPMID 30294414PMCID 6156820
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hypersensitive termination of the hypoxic response by a disordered protein switch

  2017cited by this paper
• Hypoxia inducible factor down-regulation, cancer and cancer stem cells (CSCs): ongoing success stories.

  2017cited by this paper
• The facial triad in the α-ketoglutarate dependent oxygenase FIH: A role for sterics in linking substrate binding to O2 activation.

  2017cited by this paper
• A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma.

  2016cited by this paper
• Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition

  2016cited by this paper
• Towards “bionic” proteins: replacement of continuous sequences from HIF-1α with proteomimetics to create functional p300 binding HIF-1α mimics

  2016cited by this paper
• Structural basis for oxygen degradation domain selectivity of the HIF prolyl hydroxylases

  2016cited by this paper
• Selective electrochemiluminescent sensing of saccharides using boronic acid-modified coreactant.

  2016cited by this paper
• Synthesis of highly functionalized oligobenzamide proteomimetic foldamers by late stage introduction of sensitive groups† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c6ob00078a Click here for additional data file.

  2016cited by this paper
• Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.

  2016cited by this paper
• Discovery of a VHL and HIF1α interaction inhibitor with in vivo angiogenic activity via structure-based virtual screening.

  2016cited by this paper
• On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

  2016cited by this paper
• Targeting renal cell carcinoma with a HIF-2 antagonist

  2016cited by this paper
• Small-Molecule PROTACS: New Approaches to Protein Degradation.

  2016cited by this paper
• Light-Responsive Self-Assembled Materials by Supramolecular Post-Functionalization via Hydrogen Bonding of Amphiphilic Block Copolymers

  2016cited by this paper
• Pharmacological targeting of the HIF hydroxylases--A new field in medicine development.

  2016cited by this paper
• Reprogramming the Transcriptional Response to Hypoxia with a Chromosomally Encoded Cyclic Peptide HIF-1 Inhibitor

  2016cited by this paper
• Coiled-coil Coactivators Play a Structural Role Mediating Interactions in Hypoxia-inducible Factor Heterodimerization*

  2015cited by this paper
• Isoform-Selective and Stereoselective Inhibition of Hypoxia Inducible Factor-2.

  2015cited by this paper
• Exploration of the HIF-1α/p300 interface using peptide and Adhiron phage display technologies.

  2015cited by this paper
• Structural integration in hypoxia-inducible factors

  2015cited by this paper
• Inhibition of the HIF1α-p300 interaction by quinone- and indandione-mediated ejection of structural Zn(II).

  2015cited by this paper
• Depsipeptide substrates for sortase-mediated N-terminal protein ligation

  2014cited by this paper
• Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities

  2014cited by this paper
• Chemistry: Chemical con artists foil drug discovery

  2014cited by this paper
• Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer

  2014cited by this paper
• Small-Molecule Proteomimetic Inhibitors of the HIF-1α–p300 Protein–Protein Interaction

  2014cited by this paper
• In vivo modulation of hypoxia-inducible signaling by topographical helix mimetics

  2014cited by this paper
• Rational Design of Topographical Helix Mimics as Potent Inhibitors of Protein–Protein Interactions

  2014cited by this paper
• Synthesis of Oligobenzamide α-Helix Mimetics

  2013cited by this paper
• Suppression of tumor growth by designed dimeric epidithiodiketopiperazine targeting hypoxia-inducible transcription factor complex.

  2013cited by this paper
• A Cyclic Peptide Inhibitor of HIF-1 Heterodimerization That Inhibits Hypoxia Signaling in Cancer Cells

  2013cited by this paper
• Allosteric Inhibition of Hypoxia Inducible Factor-2 with Small Molecules

  2013cited by this paper
• Development of inhibitors of the PAS-B domain of the HIF-2α transcription factor.

  2013cited by this paper
• Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases.

  2013cited by this paper
• Solid-Phase Methodology for Synthesis of O-Alkylated Aromatic Oligoamide Inhibitors of α-Helix-Mediated Protein–Protein Interactions

  2013cited by this paper
• Regulating the ARNT/TACC3 axis: multiple approaches to manipulating protein/protein interactions with small molecules.

  2013cited by this paper
• Protein domain mimetics as in vivo modulators of hypoxia-inducible factor signaling

  2013cited by this paper
• Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: structural and functional versatility in target recognition

  2013cited by this paper
• Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1α protein-protein interface.

  2012cited by this paper
• Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.

  2012cited by this paper
• Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α.

  2012cited by this paper
• 2-O-alkylated para-benzamide α-helix mimetics: the role of scaffold curvature.

  2012cited by this paper
• Arylsulfonamide KCN1 Inhibits In Vivo Glioma Growth and Interferes with HIF Signaling by Disrupting HIF-1α Interaction with Cofactors p300/CBP

  2012cited by this paper
• Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction

  2012cited by this paper
• Deep sequencing analysis of phage libraries using Illumina platform.

  2012cited by this paper
• Identification of Cys255 in HIF‐1α as a novel site for development of covalent inhibitors of HIF‐1α/ARNT PasB domain protein–protein interaction

  2012cited by this paper
• Oxygen sensing, homeostasis, and disease.

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors.

  2011cited by this paper
• Stabilizing the eIF4G1 α-helix increases its binding affinity with eIF4E: implications for peptidomimetic design strategies.

  2011cited by this paper
• Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway.

  2011cited by this paper
• Coactivators necessary for transcriptional output of the hypoxia inducible factor, HIF, are directly recruited by ARNT PAS-B

  2011cited by this paper
• Targeting tumour angiogenesis with small molecule inhibitors of hypoxia inducible factor.

  2011cited by this paper
• mechanisms of disease Oxygen Sensing , Homeostasis , and Disease

  2011cited by this paper
• Targeting HIF1α eliminates cancer stem cells in hematological malignancies.

  2011cited by this paper
• Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

  2010cited by this paper
• N-alkylated oligoamide alpha-helical proteomimetics.

  2010cited by this paper
• HSP90 at the hub of protein homeostasis: emerging mechanistic insights

  2010cited by this paper
• Inhibition of hypoxia inducible factor 1-transcription coactivator interaction by a hydrogen bond surrogate alpha-helix.

  2010cited by this paper
• Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

  2009cited by this paper
• Complex Regulation of the Transactivation Function of Hypoxia-inducible Factor-1α by Direct Interaction with Two Distinct Domains of the CREB-binding Protein/p300*

  2009cited by this paper
• Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor

  2009cited by this paper
• Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization

  2009cited by this paper
• Structural basis for binding of hypoxia-inducible factor to the oxygen-sensing prolyl hydroxylases.

  2009cited by this paper
• Principles of ligand binding within a completely buried cavity in HIF2alpha PAS-B.

  2009cited by this paper
• Epidithiodiketopiperazines Block the Interaction between Hypoxia-inducible Factor-1α (HIF-1α) and p300 by a Zinc Ejection Mechanism*

  2009cited by this paper
• The human HIF (hypoxia-inducible factor)-3alpha gene is a HIF-1 target gene and may modulate hypoxic gene induction.

  2009cited by this paper
• The human oxygen sensing machinery and its manipulation.

  2008cited by this paper
• Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11–Refractory Model

  2008cited by this paper
• Evidence That Two Enzyme-derived Histidine Ligands Are Sufficient for Iron Binding and Catalysis by Factor Inhibiting HIF (FIH)*

  2008cited by this paper
• Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1.

  2008cited by this paper
• A hydrogen bond surrogate approach for stabilization of short peptide sequences in alpha-helical conformation.

  2008cited by this paper
• Hypoxia-mediated Selective mRNA Translation by an Internal Ribosome Entry Site-independent Mechanism*

  2008cited by this paper
• Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α

  2008cited by this paper
• A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth

  2008cited by this paper
• Hypoxia: A key regulator of angiogenesis in cancer

  2007cited by this paper
• Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface.

  2007cited by this paper
• Split-intein mediated circular ligation used in the synthesis of cyclic peptide libraries in E. coli

  2007cited by this paper
• HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity.

  2007cited by this paper
• Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer

  2007cited by this paper
• Modulation of p300 binding by posttranslational modifications of the C‐terminal activation domain of hypoxia‐inducible factor‐1α

  2007cited by this paper
• Lysyl oxidase is essential for hypoxia-induced metastasis

  2006cited by this paper
• Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.

  2005cited by this paper
• Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells.

  2005cited by this paper
• Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase.

  2005cited by this paper
• Selective inhibition of factor inhibiting hypoxia-inducible factor.

  2005cited by this paper
• Overexpression of hypoxia‐inducible factor HIF‐1α predicts early relapse in breast cancer: Retrospective study in a series of 745 patients

  2005cited by this paper
• Recruitment of Thyroid Hormone Receptor/Retinoblastoma-interacting Protein 230 by the Aryl Hydrocarbon Receptor Nuclear Translocator Is Required for the Transcriptional Response to Both Dioxin and Hypoxia*

  2004cited by this paper
• Role of the Coiled-coil Coactivator (CoCoA) in Aryl Hydrocarbon Receptor-mediated Transcription*

  2004cited by this paper
• Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway.

  2004cited by this paper
• Persistent induction of HIF‐1α and ‐2α in cardiomyocytes and stromal cells of ischemic myocardium

  2004cited by this paper
• Regulation of angiogenesis by hypoxia: role of the HIF system

  2003cited by this paper
• Hypoxia-inducible Factor and Its Biomedical Relevance*

  2003cited by this paper
• Structure of Factor-inhibiting Hypoxia-inducible Factor (HIF) Reveals Mechanism of Oxidative Modification of HIF-1α*

  2003cited by this paper
• Recognition of the DNA minor groove by pyrrole-imidazole polyamides.

  2003cited by this paper
• Hypoxia inducible factor as a cancer drug target.

  2003cited by this paper
• Targeting HIF-1 for cancer therapy

  2003cited by this paper
• Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling

  2002cited by this paper
• Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1α

  2002cited by this paper

• Hypoxia-driven metabolic and molecular reprogramming: From tumor microenvironment to therapeutic interventions.

  2025cites this paper
• Acetylation: a new target for protein degradation in cancer.

  2025cites this paper
• Assessment of the Toxicity of Polystyrene Microplastic in the Colon and Liver of Adult NMRI Mice

  2025cites this paper
• Site-directed allostery perturbation to probe the negative regulation of hypoxia inducible factor-1α

  2024cites this paper
• Hypoxia-induced Factor-1α and its Role in Endometrial Cancer

  2024cites this paper
• Staufen1 controls mitochondrial metabolism via HIF2α in embryonal rhabdomyosarcoma and promotes tumorigenesis

  2023cites this paper
• Targeting hypoxia-inducible factors: therapeutic opportunities and challenges

  2023cites this paper
• Considerations about Hypoxic Changes in Neuraxis Tissue Injuries and Recovery

  2022cites this paper
• Metabolic switch in cancer - Survival of the fittest.

  2022cites this paper
• TRAP1 regulates the response of colorectal cancer cells to hypoxia and inhibits ribosome biogenesis under conditions of oxygen deprivation

  2022cites this paper
• Interfacial Peptides as Affinity Modulating Agents of Protein-Protein Interactions

  2022cites this paper
• Potent Inhibition of HIF1α and p300 Interaction by a Constrained Peptide Derived from CITED2.

  2021cites this paper
• Peptide-based inhibitors of protein–protein interactions: biophysical, structural and cellular consequences of introducing a constraint

  2021cites this paper
• Flavonoids Targeting HIF-1: Implications on Cancer Metabolism

  2021cites this paper
• Understanding p300-transcription factor interactions using sequence variation and hybridization

  2021cites this paper
• Design and synthesis of 14 and 15-membered macrocyclic scaffolds exhibiting inhibitory activities of hypoxia-inducible factor 1α.

  2020cites this paper
• Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.

  2020influential citation
• Mushroom: A New Resource for Anti-Angiogenic Therapeutics

  2020cites this paper
• Design, Synthesis, and Conformation-Activity Study of Unnatural Bridged Bicyclic Depsipeptides as Highly Potent HIF-1 Inhibitors and Antitumor Agents.

  2020cites this paper
• Stapled Peptides as HIF‐1α/p300 Inhibitors: Helicity Enhancement in the Bound State Increases Inhibitory Potency

  2020cites this paper
• A divergent mode of activation of a nitrosyl iron complex with unusual antiangiogenic activity.

  2020cites this paper
• HIF-1α Modulates Core Metabolism and Virus Replication in Primary Airway Epithelial Cells Infected with Respiratory Syncytial Virus

  2020cites this paper
• Advances in inhibition of protein-protein interactions targeting hypoxia-inducible factor-1 for cancer therapy.

  2019cites this paper
• Hypoxia-inducible factor 1 signalling, metabolism and its therapeutic potential in cardiovascular disease.

  2019cites this paper
• Hypoxia-Inducible Factors as an Alternative Source of Treatment Strategy for Cancer

  2019cites this paper
• Predicting and Experimentally Validating Hot-Spot Residues at Protein–Protein Interfaces

  2019cites this paper
• Protein Recognition by Functionalized Sulfonatocalix[4]arenes.

  2018cites this paper
• Regulation of C. elegans behavior and physiology by the hypoxia-response pathway

  2018cites this paper
• Ischaemia reperfusion injury: mechanisms of progression to chronic graft dysfunction

  2018cites this paper
• The association of the placental Hypoxia-inducible factor1-α polymorphisms and HIF1-α mRNA expression with preeclampsia.

  2018cites this paper
• Discovery of bicyclo[3,3,1]non-2-ene as a novel skeleton for HIF-1 inhibitors.

  2018cites this paper
• Hypoxia inducible factor down-regulation, cancer and cancer stem cells (CSCs): ongoing success stories.

  2017cites this paper